Release date: 8 November 2024
Promoter – Financial Intermediary
PHARMATHEN SA - INDUSTRIAL AND COMMERCIAL COMPANY OF PHARMACEUTICALS AND COSMETICSLocation
Description
The project will finance the promoter's Research and Development (R&D) investments in the period 2025-2028.
Objectives
The aim is to support Pharmathen's R&D expenditures.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 100 million
Total cost (Approximate amount)
EUR 229 million
Environmental aspects
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories Thus an Environmental Impact Assessment (EIA) is not foreseen. The RDI activities do not fall under the Annexes of the EIA Directive 2011/92/EU as amended by Directive 2014/52/EU. The full environmental details will however be investigated by the Bank's services during the due diligence stage.
Procurement
The Promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to the EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.
Status
Under appraisal - 24/09/2024
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).